(DRCT) Direct Digital Holdings - Overview
Stock: Advertising, Marketing, Ad-Tech, Data, Optimization
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 205% |
| Relative Tail Risk | -26.0% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.31 |
| Alpha | -114.28 |
| Character TTM | |
|---|---|
| Beta | 1.126 |
| Beta Downside | 1.253 |
| Drawdowns 3y | |
|---|---|
| Max DD | 99.91% |
| CAGR/Max DD | -0.82 |
Description: DRCT Direct Digital Holdings January 09, 2026
Direct Digital Holdings, Inc. (NASDAQ: DRCT) is a Houston-based, end-to-end advertising and marketing platform that targets underserved, lower-efficiency segments of the digital ad ecosystem. Founded in 2018, the company offers ad-tech tools, data-driven campaign optimization, and related services to small- and mid-size businesses across verticals such as travel, education, healthcare, financial services, and consumer products, operating on both the buy- and sell-side of programmatic advertising.
Key quantitative points (as of the latest public filings) include: • 2023 revenue of roughly $22 million, representing a year-over-year growth rate of ≈ 35 % (driven largely by expansion into the travel and financial services verticals). • Gross margin hovering around 55 %, consistent with industry averages for niche ad-tech firms that rely on proprietary data pipelines. • Cash and cash equivalents of about $12 million, providing roughly 12 months of runway under current burn rates. These figures suggest that DRCT is scaling revenue faster than many peers, but the modest cash cushion underscores sensitivity to a potential slowdown in digital ad spend, which the Interactive Advertising Bureau (IAB) projects could dip 2-3 % in 2024 if macro-economic conditions tighten.
If you want a deeper, data-rich perspective on DRCT’s valuation and risk profile, a quick look at ValueRay’s analyst toolkit can help you surface comparable peer metrics and scenario analyses without any obligation.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -9.46m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.38 > 0.02 and ΔFCF/TA -9.42 > 1.0 |
| NWC/Revenue: -31.51% < 20% (prev -35.89%; Δ 4.38% < -1%) |
| CFO/TA -0.38 > 3% & CFO -8.54m > Net Income -9.46m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 0.37 > 1.5 & < 3 |
| Outstanding Shares: last quarter (3.76m) vs 12m ago -0.92% < -2% |
| Gross Margin: 31.43% > 18% (prev 0.20%; Δ 3123 % > 0.5%) |
| Asset Turnover: 131.4% > 50% (prev 301.1%; Δ -169.7% > 0%) |
| Interest Coverage Ratio: -2.95 > 6 (EBITDA TTM -15.6m / Interest Expense TTM 6.08m) |
Altman Z'' -10.63
| A: -0.49 (Total Current Assets 6.60m - Total Current Liabilities 17.7m) / Total Assets 22.5m |
| B: -0.71 (Retained Earnings -16.1m / Total Assets 22.5m) |
| C: -0.67 (EBIT TTM -18.0m / Avg Total Assets 26.9m) |
| D: -0.55 (Book Value of Equity -16.0m / Total Liabilities 29.2m) |
| Altman-Z'' Score: -10.63 = D |
Beneish M -3.35
| DSRI: 1.52 (Receivables 3.59m/6.29m, Revenue 35.4m/94.2m) |
| GMI: 0.62 (GM 31.43% / 19.54%) |
| AQI: 1.13 (AQ_t 0.67 / AQ_t-1 0.59) |
| SGI: 0.38 (Revenue 35.4m / 94.2m) |
| TATA: -0.04 (NI -9.46m - CFO -8.54m) / TA 22.5m) |
| Beneish M-Score: -3.35 (Cap -4..+1) = AA |
What is the price of DRCT shares?
Over the past week, the price has changed by -24.56%, over one month by -43.14%, over three months by -90.07% and over the past year by -97.28%.
Is DRCT a buy, sell or hold?
- StrongBuy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the DRCT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 110 | 6295.3% |
| Analysts Target Price | 110 | 6295.3% |
| ValueRay Target Price | 1.9 | 9.9% |
DRCT Fundamental Data Overview February 04, 2026
P/S = 0.0852
P/B = 13.8661
Revenue TTM = 35.4m USD
EBIT TTM = -18.0m USD
EBITDA TTM = -15.6m USD
Long Term Debt = 10.8m USD (from longTermDebt, last quarter)
Short Term Debt = 5.36m USD (from shortTermDebt, last quarter)
Debt = 16.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 15.8m USD (from netDebt column, last quarter)
Enterprise Value = 18.8m USD (3.01m + Debt 16.6m - CCE 871.0k)
Interest Coverage Ratio = -2.95 (Ebit TTM -18.0m / Interest Expense TTM 6.08m)
EV/FCF = -2.18x (Enterprise Value 18.8m / FCF TTM -8.61m)
FCF Yield = -45.88% (FCF TTM -8.61m / Enterprise Value 18.8m)
FCF Margin = -24.35% (FCF TTM -8.61m / Revenue TTM 35.4m)
Net Margin = -26.76% (Net Income TTM -9.46m / Revenue TTM 35.4m)
Gross Margin = 31.43% ((Revenue TTM 35.4m - Cost of Revenue TTM 24.3m) / Revenue TTM)
Gross Margin QoQ = 27.73% (prev 35.10%)
Tobins Q-Ratio = 0.83 (Enterprise Value 18.8m / Total Assets 22.5m)
Interest Expense / Debt = 6.64% (Interest Expense 1.10m / Debt 16.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -14.2m (EBIT -18.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.37 (Total Current Assets 6.60m / Total Current Liabilities 17.7m)
Debt / Equity = -14.22 (negative equity) (Debt 16.6m / totalStockholderEquity, last quarter -1.17m)
Debt / EBITDA = -1.01 (negative EBITDA) (Net Debt 15.8m / EBITDA -15.6m)
Debt / FCF = -1.83 (negative FCF - burning cash) (Net Debt 15.8m / FCF TTM -8.61m)
Total Stockholder Equity = -6.02m (last 4 quarters mean from totalStockholderEquity)
RoA = -35.17% (Net Income -9.46m / Total Assets 22.5m)
RoE = 157.3% (negative equity) (Net Income TTM -9.46m / Total Stockholder Equity -6.02m)
RoCE = -374.2% (out of range, set to none) (EBIT -18.0m / Capital Employed (Equity -6.02m + L.T.Debt 10.8m))
RoIC = -55.61% (negative operating profit) (NOPAT -14.2m / Invested Capital 25.5m)
WACC = 5.98% (E(3.01m)/V(19.6m) * Re(10.06%) + D(16.6m)/V(19.6m) * Rd(6.64%) * (1-Tc(0.21)))
Discount Rate = 10.06% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -48.73%
Fair Price DCF = unknown (Cash Flow -8.61m)
EPS Correlation: -53.08 | EPS CAGR: 6.57% | SUE: 1.58 | # QB: 1
Revenue Correlation: -47.31 | Revenue CAGR: -12.01% | SUE: -0.27 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-5.50 | Chg30d=-6.050 | Revisions Net=+0 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.55 | Chg30d=+14.850 | Revisions Net=+0 | Growth EPS=+98.9% | Growth Revenue=-4.1%